Navigation Links
Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Company's Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Date:12/5/2012

e potential to significantly improve the way the disease is managed for these patients," said Robert Williamson, Chief Executive Officer.

BCI-632 increases synaptic glutamate by inhibiting the mGlu2/3 auto-receptor, which is located predominantly at the pre-synaptic site.  As in the case of ketamine, the long-lasting efficacy of BCI-632 can be blocked by either inhibition of AMPA receptors, mTOR or the BDNF signaling pathway.  In addition, BCI-632 also stimulates serotonin release and, after chronic dosing, hippocampal neurogenesis. 

 "BCI-838 is an oral prodrug for the active agent BCI-632 that is the leading mGluR2/3 antagonist in development," said John Hutchinson, Ph.D. Senior Vice President of Research.  "The successful completion of this Phase 1 trial, coupled with the encouraging qEEG data, offers promise that the drug will demonstrate efficacy in further clinical studies."

"BCI-838 may yield meaningful clinical benefits for patients suffering from TRD.  We believe that BCI-838 may generate early antidepressant responses similar to ketamine with a better safety profile and less adverse event liability.  Unlike ketamine, BCI-838 is an oral drug with no need for intravenous administration.  Furthermore, the neurogenic effect of BCI-838 in the hippocampus suggests that BCI-838 may be a novel treatment for a broader population of patients with mood or cognitive disorders," said Steven D. Targum. M.D., Chief Medical Officer.  "We look forward to the clinical advancement of this compound in a PoC study targeted for initiation in patients with TRD at the beginning of 2013."

About TRD and MDD

Major Depressive Disorder (MDD) is a highly prevalent disorder causing marked social and economic problems for affected patients and their families.  According to the World Health Organization, MDD is the leading cause of disability worldwide.  MDD is associated with high morbidity contr
'/>"/>

SOURCE BrainCells Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tria Beauty, Inc. Announces Partnership with Jenny McCarthy
2. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
3. UBM Canon Announces its New Medical Technology Seminar Series
4. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Ultra Clean Announces Participation in the Midtown CAP Summit Investor Conference
7. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
8. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. GDS International Announces "Industry Leader of the Year" Award at its Fourth Annual European Pharmaceutical Drug Discovery Summit
11. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)...  Indianapolis interventional medical device maker NICO ... 3D visualization leader Synaptive Medical announced ... Meeting that they have joined forces to integrate ... is the first of its kind and will ... NICO,s BrainPath® interventional access technology and Synaptive,s BrightMatter™ ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused ... Food and Drug Administration ("FDA") accepted the Company,s ... of AR-12, a potentially first-in-class, orally available, PDK1 ... the endoplasmic reticulum stress pathway. Acceptance of ...
... ValueOptions(R), Inc., the nation,s largest ... support for the use of The Joint Commission,s ... basis for the recently completed pilot program was ... to help patients receive the most appropriate and ...
Cached Medicine Technology:FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services 2
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a ... the face, it certainly can be difficult to choose the ... extra favor by doing it the healthy way? Set aside ... to your body, exercise regularly, and choose foods with the ... weight; you need to exercise more and eat less. Despite ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Health Research (CIHR) announced its latest awards for injury ... two of them were headed by doctors at St. ... a team studying traumatic brain injuries (TBI). Researchers working ... will examine rural Canadians, access to trauma centres. ...
... available in Spanish . The incidence ... time. The phenomenon brings with it the possibility of neurological, ... in the short and the medium term. These consequences also ... is currently known that the progress of a premature baby ...
... about making errors, according to a new study published ... Association for Psychological Science. The researchers measured brain waves ... mistakes on a test. Those who had been prepared ... mistakes than those who hadn,t. "Eighty-five percent of ...
... Reporter , TUESDAY, Aug. 3 (HealthDay News) -- Stroke patients ... may not be protected from second strokes or heart ... association between homocysteine, an amino acid, in the blood, and ... supplements lower homocysteine levels, but whether this really has an ...
... a model that will enable them to investigate, for the ... they are in the womb. Until now it has been ... this discovery will enable researchers to understand the processes that ... (TGCC) in young adult life, and how factors, such as ...
... Gardner HealthDay Reporter , TUESDAY, Aug. 3 (HealthDay ... to an emergency room with a violent injury and who ... new research finds. The authors calculated that for every ... violent episode in the future. The study was funded ...
Cached Medicine News:Health News:St. Michael's receives prestigious grants to study trauma 2Health News:Mothers of premature children run greater risk of suffering stress 2Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 3Health News:Scientists develop the first model for investigating the origins of testicular cancer in humans 2Health News:One Therapy Session in ER Can Cut Teen Violence 2Health News:One Therapy Session in ER Can Cut Teen Violence 3
... West Nile Virus IgM Capture,DxSelect is ... West Nile virus in human serum. ... Nile Virus IgG DxSelect,the test is ... of,meningioencephalitis, as an aid in the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
... for its full line of 96- and ... quality, PerkinElmer Robotic Certified Tips are specially ... throughput applications. Tips for 96-channel pipettors are ... L to 235 L. Tips for 384-channel ...
Medicine Products: